Stroke
-
Rivaroxaban significantly reduces risk of stroke
In Bayer ’s double-blind phase 3, ROCKET AF trial, rivaroxaban demonstrated superiority to warfarin in reducing the risk of stroke and non-CNS systemic embolism in patients with atrial fibrillation (AF). Importantly, rates of bleeding were simi…
Stroke | 29 December 2010
-
GlobalData Forecasts Trends in Acute Ischemic Stroke Market to 2015
The industry report, “Acute Ischemic Stroke – Drug Pipeline Analysis and Market Forecasts to 2015†by GlobalData identifies the key trends that are shaping and driving the global Acute Ischemic Stroke (AIS) market. The global AIS market is …
Stroke | 13 January 2010
-
Neurosciences Institute Discovers Drug Extends Stroke Treatment Time to 24 Hours
Scientists at the Blanchette Rockefeller Neurosciences Institute (BRNI) have discovered that Bryostatin – and a related class of drugs discovered at BRNI – administered 24 hours after stroke, could rescue and repair brain tissue. These findi…
Stroke | 01 October 2008
-
Extending stroke treatment time to 24 hours
Scientists at the Blanchette Rockefeller Neurosciences Institute (BRNI) have discovered that Bryostatin - and a related class of drugs discovered at BRNI - administered 24 hours after stroke can rescue and repair brain tissue. These findings are …
Stroke | 05 September 2008
-
Reducing the risk of heart attack and stroke in patients with diseases
Pfizer Inc says in patients with heart disease, type 2 diabetes and chronic kidney disease, Lipitor (atorvastatin calcium) 80 mg significantly reduced the risk of major cardiovascular events, including heart attack and stroke, by 35% compared with Li…
Stroke | 11 August 2008
-
Reduction in stroke and cardiovascular events in landmark Jikei Heart Study
New findings from the independent Jikei Heart Study, published in The Lancet, show that adding the blood pressure lowering medication Diovan to conventional therapy produced a dramatic 39% reduction in cardiovascular events and a 40% reduction in str…
Stroke | 30 April 2007
